Disease State: Basal Cell Carcinoma
Basal cell carcinoma (BCC) is the most common malignancy among Caucasian populations. In addition to risk of local destruction, BCC can be associated with pain, functional sensory loss, disfigurement and psychosocial impact. Some patients develop many primary BCCs over many years, thereby experiencing BCC as a chronic disease. There are many effective treatments for BCC, including surgical excision, electrodessication, cryotherapy, topical medications, radiation, chemotherapy, and immunotherapy. Comparison of treatments for BCC, and different manifestations of BCC, is hindered by the lack of a standardized set of outcomes. A core outcome set for BCC would be expected to improve researchers’ ability to assess the relative benefits of the diversity of available therapies.
We aim to develop a core outcome set by (1) identifying all current outcomes from a systematic review of literature; (2) involving other stakeholder groups such as other clinicians, and regulators to participate in identifying additional outcomes; (3) conducting Delphi consensus exercises on the identified outcomes; (4) presenting all results from the Delphi exercises during a face-to-face (if possible) consensus meeting to vote and agree upon a core set of outcomes important for basal cell carcinoma.
Key Project Team Members
Todd V. Cartee
C3 Methods Partner
Murad Alam (email@example.com)
- Schlessinger DI, Iyengar S, Yanes AF, Lazaroff JM, Godinez-Puig V, Chen BR, Kurta AO, Henley JK, Chiren SG, Furlan KC, Schmitt J, Deckert S, Poon E, Sobanko JF, Cartee TV, Alam M, Maher IA. Development of a core outcome set for clinical trials in basal cell carcinoma: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. Trials. 2017;18(1):490. https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-017-2244-5
Updated on May 1, 2022